[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity]. 2017

Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
First Dept. of Internal Medicine, Toyama University Hospital.

A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging(MRI).Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRI findings were obtained.However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena.We switched the treatment to afatinib monotherapy, and his consciousness improved immediately.Progression -free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9.4 months, respectively. This clinical course suggests activity of afatinib for central nervous system lesions of EGFRmutated lung cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069347 Erlotinib Hydrochloride A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER. 11C-erlotinib,CP 358,774,CP 358774,CP-358,774,CP-358774,Erlotinib,Erlotinib HCl,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine,OSI-774,Tarceva,11C erlotinib,358,774, CP,358774, CP,CP358,774,CP358774,HCl, Erlotinib,Hydrochloride, Erlotinib,OSI 774,OSI774
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000077716 Afatinib A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. (2E)-N-(4-(3-Chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide,Afatinib Dimaleate,Afatinib Maleate,BIBW 2992,BIBW-2992,BIBW-2992-MA2,BIBW-2992MA2,BIBW2992,BIBW2992 MA2,Gilotrif,BIBW 2992 MA2,BIBW 2992MA2
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
January 2016, Internal medicine (Tokyo, Japan),
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
September 2014, Lung cancer (Amsterdam, Netherlands),
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
August 2018, BMC cancer,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
January 2016, Case reports in oncology,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
October 2017, Asia-Pacific journal of clinical oncology,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
April 2017, Japanese journal of clinical oncology,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
December 2016, Investigational new drugs,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
April 2019, International cancer conference journal,
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
August 2012, Lung cancer (Amsterdam, Netherlands),
Hiroaki Tanaka, and Minehiko Inomata, and Ryuji Hayashi, and Kazuki Shimokawa, and Kotaro Tokui, and Seisuke Okazawa, and Kenta Kambara, and Toru Yamada, and Toshiro Miwa, and Tatsuhiko Kashii, and Hirofumi Konishi, and Kazuyuki Tobe
May 2005, European journal of gastroenterology & hepatology,
Copied contents to your clipboard!